The Swiss drugmaker thinks of itself as a biotech star. But a series of problems with existing drugs and upcoming products has slowed its momentum. Is CEO Severin Schwan on the right track?
For pdf: http://r.reuters.com/sed24p
Our Standards: The Thomson Reuters Trust Principles.
